Finerenone dosage adjustment and analysis of individualized treatment plans

Finerenone is a new type of non-steroidal mineral corticosteroid receptor antagonist. It is mainly used to treat patients with chronic kidney disease combined with type 2 diabetes. It can effectively reduce the occurrence of cardiorenal events. Due to the large differences between patients' conditions and individuals, reasonable dosage adjustment and individualized treatment plans are crucial to ensure efficacy and safety.

First, the initial dose of fenelidone is usually determined based on the patient's renal function and serum potassium levels. For patients with good renal function and normal serum potassium, the recommended starting dose is 10mg once daily; for patients with poor renal function or at risk of mild hyperkalemia, the recommended starting dose is 5mg once daily. Dose adjustment should be based on changes in renal function and serum potassium monitoring results during treatment to avoid serious adverse reactions such as hyperkalemia caused by excessive dosage.

Secondly, individualized treatment plans emphasize regular monitoring of serum potassium and renal function indicators. In the early stage of treatment, serum potassium levels need to be monitored every 4 weeks. If the serum potassium rises to 5.5 mmol/L or above, consideration should be given to reducing the dose or suspending the medication, and then evaluating whether to resume medication after the serum potassium returns to normal. For patients with continued decline in renal function, the dose should also be adjusted promptly or treatment terminated. In addition, when other drugs that may affect potassium levels are used together, the dosage should be adjusted carefully and monitoring should be strengthened.

Finally, individualized medication of fenelidone not only focuses on dose adjustment, but also requires the development of a comprehensive treatment plan based on the patient's overall condition. Doctors should evaluate the patient's heart and kidney function, concomitant medications, lifestyle and other factors, and reasonably arrange follow-up and testing frequency. At the same time, patient education should be strengthened to remind them to pay attention to potassium intake in the diet and monitor discomfort symptoms. Through precise dosage adjustment and scientific management, the therapeutic advantages of fenelidone can be maximized to ensure patient safety.

Reference materials:https://www.kerendia.com/